Search Results - "Yuan, Maoxi"

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Investigation on Potential Correlation Between Small Nuclear Ribonucleoprotein Polypeptide A and Lung Cancer by Yuan, Maoxi, Yu, Chunmei, Chen, Xin, Wu, Yubing

    Published in Frontiers in genetics (21-01-2021)
    “…(small nuclear ribonucleoprotein polypeptide A) gene is essential for the pre-mRNA splicing process. Using the available datasets of TCGA or GEO, we aimed at…”
    Get full text
    Journal Article
  2. 2

    Association of human XPA rs1800975 polymorphism and cancer susceptibility: an integrative analysis of 71 case-control studies by Yuan, Maoxi, Yu, Chunmei, Yu, Kuiying

    Published in Cancer cell international (13-05-2020)
    “…The objective of the present study is to comprehensively evaluate the impact of the rs1800975 A/G polymorphism within the human xeroderma pigmentosum group A (…”
    Get full text
    Journal Article
  3. 3

    Non-small cell lung cancer: miR-30d suppresses tumor invasion and migration by directly targeting NFIB by Wu, Yubing, Zhang, Jingnan, Hou, Shizhen, Cheng, Ziming, Yuan, Maoxi

    Published in Biotechnology letters (01-12-2017)
    “…Objective To evaluate the role and the molecular mechanism of miR-30d in non-small cell lung cancer (NSCLC). Results qRT-PCR was used to detect miR-30d…”
    Get full text
    Journal Article
  4. 4

    LINC01419 promotes cell proliferation and metastasis in lung adenocarcinoma via sponging miR-519b-3p to up-regulate RCCD1 by Cheng, Ziming, Hou, Shizhen, Wu, Yubing, Wang, Xiangdong, Sun, Yi, Liu, Bing, Yuan, Maoxi

    “…Lung adenocarcinoma (LUAD) is one of the most common type of lung cancer notorious for the high incidence and mortality around the world. Long non-coding RNAs…”
    Get full text
    Journal Article
  5. 5

    Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis by Liu, Bing, Yuan, Maoxi, Sun, Yi, Cheng, Ziming, Zhang, Zaiyong, Hou, Shizheng, Wang, Xiangdong, Liu, Jingfeng

    Published in Oncotarget (06-02-2018)
    “…Two anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (-TKIs) have been approved for the treatment of patients with ALK-rearranged (ALK-positive)…”
    Get full text
    Journal Article